


## Tipiracil hydrochloride

<b>Cat. No.:</b>	HY-A0063
<b>CAS No.:</b>	183204-72-0
<b>Molecular Formula:</b>	C <sub>9</sub> H <sub>12</sub> Cl <sub>2</sub> N <sub>4</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	279
<b>Target:</b>	Nucleoside Antimetabolite/Analog
<b>Pathway:</b>	Cell Cycle/DNA Damage
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 50 mg/mL (179.21 mM; Need ultrasonic)					
	DMSO : < 1 mg/mL (insoluble or slightly soluble)					
	DMF : < 1 mg/mL (insoluble)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
<b>1 mM</b>			3.5842 mL	17.9211 mL	35.8423 mL	
<b>5 mM</b>			0.7168 mL	3.5842 mL	7.1685 mL	
	<b>10 mM</b>		0.3584 mL	1.7921 mL	3.5842 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 25 mg/mL (89.61 mM); Clear solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tipiracil (hydrochloride) is a thymidine phosphorylase inhibitor (TPI), used for cancer research.
<b>In Vitro</b>	Tipiracil has antiangiogenic effect, and inhibits proliferation of endothelial cells <sup>[1]</sup> . Tipiracil is a potent inhibitor of thymidine phosphorylase, which is the enzyme that degrades FTD <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Biomed Pharmacother. 2021 May 6;139:111672.

- 
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
  - Oncol Rep. 2023 Mar;49(3):52.
  - Mod Rheumatol. 2018 May;28(3):495-505.
  - Patent. US Patent 11110111.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Peters GJ, et al. TAS-102: more than an antimetabolite. Lancet Oncol. 2012 Dec;13(12):e518-9.

[2]. Yoshino T, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012 Oct;13(10):993-1001.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA